Acadia Pharmaceuticals Inc. insider trading
This tab shows only the shares insiders bought or sold on the open market in the last twelve months (Form 4 codes P and S). Grants, option exercises, shares held back for tax and gifts are left out on purpose, so what is left is insiders trading at the market price like anyone else.
In the last twelve months insiders at Acadia Pharmaceuticals Inc. filed 24 open-market sales worth $3.4 million and 0 open-market purchases, on Form 4 with the SEC. The latest: Schneyer Mark C., EVP, Chief Financial Officer, sold 5,000 shares at $29.00 on 6 August 2026, filed 7 August 2026.
| Traded | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 6 August 2026 | Schneyer Mark C. | EVP, Chief Financial Officer | Sale | 5,000 | $29.00 | $145,000 | Form 4 |
| 6 August 2026 | Schneyer Mark C. | EVP, Chief Financial Officer | Sale | 9,292 | $29.34 | $272,604 | Form 4 |
| 5 August 2026 | Schneyer Mark C. | EVP, Chief Financial Officer | Sale | 5,849 | $29.00 | $169,638 | Form 4 |
| 30 July 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sale | 16,508 | $26.13 | $431,354 | Form 4 |
| 30 July 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sale | 50 | $26.17 | $1,308 | Form 4 |
| 26 June 2026 | Kihara James | Principal Accounting Officer | Sale | 11,421 | $26.08 | $297,912 | Form 4 |
| 26 May 2026 | Kihara James | Principal Accounting Officer | Sale | 5,401 | $21.18 | $114,393 | Form 4 |
| 4 May 2026 | Kihara James | Principal Accounting Officer | Sale | 1,332 | $21.79 | $29,024 | Form 4 |
| 4 May 2026 | Schneyer Mark C. | EVP, Chief Financial Officer | Sale | 3,506 | $21.79 | $76,396 | Form 4 |
| 7 April 2026 | Schneyer Mark C. | EVP, Chief Financial Officer | Sale | 2,709 | $22.20 | $60,140 | Form 4 |
| 7 April 2026 | Kihara James | Principal Accounting Officer | Sale | 1,030 | $22.20 | $22,866 | Form 4 |
| 26 March 2026 | Kihara James | Principal Accounting Officer | Sale | 1,097 | $21.65 | $23,750 | Form 4 |
| 26 March 2026 | Kihara James | Principal Accounting Officer | Sale | 12 | $21.73 | $261 | Form 4 |
| 26 March 2026 | Schneyer Mark C. | EVP, Chief Financial Officer | Sale | 3,171 | $21.65 | $68,652 | Form 4 |
| 26 March 2026 | Schneyer Mark C. | EVP, Chief Financial Officer | Sale | 37 | $21.72 | $804 | Form 4 |
| 25 March 2026 | Owen Adams Catherine | Chief Executive Officer | Sale | 11,641 | $21.47 | $249,932 | Form 4 |
| 25 March 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sale | 3,435 | $21.47 | $73,749 | Form 4 |
| 25 March 2026 | Rhodes Jennifer J | EVP, Chief Legal Officer, SEC | Sale | 3,844 | $21.47 | $82,531 | Form 4 |
| 25 March 2026 | Kihara James | Principal Accounting Officer | Sale | 833 | $21.47 | $17,885 | Form 4 |
| 25 March 2026 | Schneyer Mark C. | EVP, Chief Financial Officer | Sale | 4,177 | $21.47 | $89,680 | Form 4 |
| 9 February 2026 | Rhodes Jennifer J | EVP, Chief Legal Officer, SEC | Sale | 6,950 | $23.38 | $162,491 | Form 4 |
| 18 November 2025 | Schneyer Mark C. | EVP, Chief Financial Officer | Sale | 10,262 | $23.69 | $243,114 | Form 4 |
| 18 November 2025 | Kihara James | Principal Accounting Officer | Sale | 4,084 | $23.69 | $96,754 | Form 4 |
| 10 November 2025 | Daly James M | Director | Sale | 30,000 | $22.37 | $670,983 | Form 4 |
A filing with several lines appears once per line.
Source
Form 4 filings on EDGAR for Acadia Pharmaceuticals Inc.: the company's filing index.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.